Sensibilidade a fungicidas de isolados de corynespora cassiicola provenientes do Estado de Goiás.

O fungo Corynespora cassiicola, agente causal da mancha-alvo em soja, pode, sob condições de alta temperatura e alta umidade, causar sérios danos à cultura. No Brasil, não se tem condições suficientes para um manejo adequado dessa doença, principalmente pela escassez de fungicidas foliares registrados e cultivares resistentes. Este trabalho foi realizado visando avaliar a sensibilidade in vitro de seis isolados de C. cassiicola oriundos do Estado de Goiás, aos fungicidas boscalida, carbendazim, ciproconazol, fluopyram, fluxapiroxade, protioconazol e tiofanato-metílico, utilizados nas concentrações de 0; 0,01; 0,1; 1; 10 e 100 ug mL-1 de ingrediente ativo (i.a.). Os fungicidas fluxapiroxade e fluopyram proporcionaram as maiores inibições de crescimento micelial (ICM) do patógeno in vitro, apresentando as menores doses efetivas capaz de inibir o crescimento micelial em 50% (DE50). O fungicida tiofanato-metílico foi incapaz de inibir o crescimento micelial do fungo nas concentrações avaliadas

Photoelectron angular distribution studies for two spin\u2013orbit-split components of Xe 3d subshell: a critical comparison between theory and experiment

The photoelectron angular distribution asymmetry parameters \u3b2 of the Xe 3d subshell were investigated using an x-ray free-electron laser (XFEL) at photon energies of 750 and 800 eV. Owing to the perfect polarization of the XFEL and two-dimensional momentum imaging capability of our velocity map imaging spectrometer, we determined the \u3b2 values with high accuracy. The \u3b2 values were also investigated based on relativistic time-dependent density functional theory calculations of up to 900 eV of photon energies. By comparing all the available experimental results including our data with the most reliable theories on the photon energy dependence of the \u3b2 parameters, serious differences are noted between the experiments and theories. Further studies on resolving this difference will provide new insight into the photoionization processes of the deep inner shells

A search for non-random cosmic-ray time series by a cluster analysis

Non-random time series of cosmic rays were searched for in air shower data of mean energy 1:1 x 1015 eV, collected by the air shower array atMitsuishi, Japan, during the period from January 1989 to October 1996. By clustering the arrival time of air showers, five occasions of rate elevation phenomena were found with an expected probability 0:05 (varying from 0:18 x 1

Study of Two-Proton States of the 20Ne Nucleus by (3He, n) Reaction

開始ページ、終了ページ: 冊子体のページ付

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin : ODYSSEY NIPPON study design and rationale

Background: Statins are generally well-tolerated and serious side effects are infrequent, but some patients experience adverse events and reduce their statin dose or discontinue treatment altogether. Alirocumab is a highly specific, fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), which can produce substantial and sustained reductions of low-density lipoprotein cholesterol (LDL-C). Methods: The randomized, double-blind, placebo-controlled, parallel-group, phase 3 ODYSSEY NIPPON study will explore alirocumab 150 mg every 4 weeks (Q4W) in 163 Japanese patients with hypercholesterolemia who are on the lowest-strength dose of atorvastatin (5 mg/day) or are receiving a non-statin lipid-lowering therapy (LLT) (fenofibrate, bezafibrate, ezetimibe, or diet therapy alone). Hypercholesterolemia is defined as LDL-C ≥ 100 mg/dL (2.6 mmol/L) in patients with heterozygous familial hypercholesterolemia or non-familial hypercholesterolemia with a history of documented coronary heart disease, or ≥120 mg/dL (3.1 mmol/L) in patients with non-familial hypercholesterolemia classified as primary prevention category III (i.e. high-risk patients). During the 12-week double-blind treatment period, patients will be randomized (1:1:1) to receive alirocumab subcutaneously (SC) 150 mg Q4W alternating with placebo for alirocumab Q4W, or alirocumab 150 mg SC every 2 weeks (Q2W), or SC placebo Q2W. The primary efficacy endpoint is the percentage change in calculated LDL-C from baseline to week 12. The long-term safety and tolerability of alirocumab will also be investigated. Discussion: The ODYSSEY NIPPON study will provide insights into the efficacy and safety of alirocumab 150 mg Q4W or 150 mg Q2W among Japanese patients with hypercholesterolemia who are on the lowest-strength dose of atorvastatin, or are receiving a non-statin LLT (including diet therapy alone)